CTLA4 and cutaneous melanoma: Among the inhibitory checkpoints, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are the most studied and are promising targets for cutaneous melanoma treatment.